Total Funding
8
Total FundingSeed raised
Growth Score
pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
Oxygen Therapy is a biopharma company that develops anti-necrosis drugs that treat a variety of medical conditions resulting from Ischemia.
Ola Soderquist: CFO/Controller & Co-founderPast Role: Faria Beede Instruments, CFO
David Platt: CEO
About the Company
Oxygen Therapy is a biopharma company that develops anti-necrosis drugs that treat a variety of medical conditions resulting from Ischemia. The company focuses on the development and commercialization of first-in-class treatments to prevent catastrophic brain damage resulting from hypoxic conditions following a brain stroke.
The Company’s lead
product candidate, OTI-629, is an anti-necrosis drug that carries oxygen to tissues when the flow of blood is blocked. It will be tested as a potent resuscitative agent to treat Ischemic brain strokes, also known as Cardiac Cerebrovascular Accidents (CVA). In addition, their drug candidate OTI-1011, will be tested as a resuscitative agent in a variety of wound healing applications.
